Should New FILSPARI Data Require Action From Travere Therapeutics Stock Investors?

Simply Wall St.10-07

Travere Therapeutics reported new FILSPARI data at ASN Kidney Week 2026, with SPARTAN, DUPLEX and PROTECT results underscoring efficacy, renal protection signals and safety in IgA nephropathy and FSGS...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2673498095?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-07 14:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2673498095","market":"us","top_or_hot":-1,"title":"Should New FILSPARI Data Require Action From Travere Therapeutics Stock Investors?","media":"Simply Wall St.","content":"<div>\n<p>Travere Therapeutics reported new FILSPARI data at ASN Kidney Week 2026, with SPARTAN, DUPLEX and PROTECT results underscoring efficacy, renal protection signals and safety in IgA nephropathy and FSGS...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/should-new-filspari-data-require-action-from-travere-therape\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should New FILSPARI Data Require Action From Travere Therapeutics Stock Investors?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould New FILSPARI Data Require Action From Travere Therapeutics Stock Investors?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-07 14:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/should-new-filspari-data-require-action-from-travere-therape><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Travere Therapeutics reported new FILSPARI data at ASN Kidney Week 2026, with SPARTAN, DUPLEX and PROTECT results underscoring efficacy, renal protection signals and safety in IgA nephropathy and FSGS...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/should-new-filspari-data-require-action-from-travere-therape\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/should-new-filspari-data-require-action-from-travere-therape","article_id":"2673498095","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/should-new-filspari-data-require-action-from-travere-therape","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2673498095","pubTimestamp":1791354237,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Travere Therapeutics reported new FILSPARI data at ASN Kidney Week 2026, with SPARTAN, DUPLEX and PROTECT results underscoring efficacy, renal protection signals and safety in IgA nephropathy and FSGS, alongside real world and molecular findings.\nThe USPTO Notice of Allowance for a new FSGS use patent and an issued IgAN patent extend FILSPARI method-of-use protection into 2037, which matters for Travere Therapeutics’ pricing power, competitive position and long term planning around its lead...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","FFTY":"Innovator IBD 50 ETF","LFSC":"F/m Emerald Life Sciences Innovation ETF","BK4139":"生物科技","ISBC":"投资者银行","LENZ":"Therapeutics","BK4007":"制药","BK4211":"区域性银行","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","TVTX":"Travere Therapeutics, Inc."},"translate_title":"新的 FILSPARI 数据是否需要 Travere Therapeutics 股票投资者采取行动？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":0.9,"LFSC":0.6,"FFTY":1.5,"ISBC":1.5,"LENZ":1.5},"content_text":"Travere Therapeutics reported new FILSPARI data at ASN Kidney Week 2026, with SPARTAN, DUPLEX and PROTECT results underscoring efficacy, renal protection signals and safety in IgA nephropathy and FSGS, alongside real world and molecular findings. The USPTO Notice of Allowance for a new FSGS use patent and an issued IgAN patent extend FILSPARI method-of-use protection into 2037, which matters for Travere Therapeutics’ pricing power, competitive position and long term planning around its lead renal asset. We will now examine how Travere Therapeutics' investment narrative could shift given stronger FILSPARI renal data presented at ASN.  Scan beyond Travere Therapeutics and size up other kidney care players with resilient finances using our hand picked list of solid balance sheet and fundamentals (25 results) as a starting universe. AdvertisementTravere Therapeutics Investment Narrative Recap To own Travere Therapeutics, you need to believe FILSPARI can support a focused rare kidney business while the rest of the portfolio pulls its weight. The key near term swing factor is execution in IgA nephropathy and potential FSGS expansion. The fresh ASN Kidney Week data directly feeds into that, since it speaks to how physicians may view FILSPARI in real practice. The biggest risk still sits in concentration. Travere leans heavily on FILSPARI while facing R&D and commercial spending that can weigh on cash flow. Stronger proteinuria, biomarker and safety data can help soften regulatory and payer risk, but do not remove competitive pressure or pricing pushback. The October ASN update on FILSPARI looks most relevant for the catalyst path. Final SPARTAN results in newly diagnosed IgA nephropathy, plus DUPLEX and PROTECT readouts, give clinicians and regulators a deeper view of efficacy, eGFR trends and biomarker shifts. That evidence matters if you care about label expansion, treatment guidelines and how quickly FILSPARI moves earlier in the care journey. At the same time, the recent US patent allowance for FSGS use out to 2037 ties directly into that clinical story. Extended method of use protection, combined with data in FSGS patients without nephrotic syndrome, shapes how long Travere might enjoy pricing power if regulators grant broader approval. It also influences how management plans long run spending, manufacturing and partnering around this single key asset. Travere Therapeutics' current analyst narrative points to revenues of US$1.5b and earnings of US$455.1 million by 2029, built on forecast top line expansion of 35.7% a year and a swing in earnings of roughly US$522.8 million from a loss of US$67.7 million today to that 2029 consensus profit. Uncover why Travere Therapeutics' fair value signals a 32% potential upside to its current price and a valuation gap that may not last much longer. NasdaqGM:TVTX 1-Year Stock Price Chart Exploring Other Perspectives One alternate view on Travere Therapeutics puts pricing pressure at the center of the story. Before this ASN news, the most cautious analysts were only modeling about US$1.2b of revenue and roughly US$293.9 million in earnings by 2029. That is far below the optimistic camp. This is why it helps to compare several narratives yourself, then decide how this fresh data might shift them. Explore 3 other Travere Therapeutics fair value estimates, including one that suggests it could be worth just $74.14! Decide For Yourself Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.  A great starting point for your Travere Therapeutics research is our analysis highlighting 4 key rewards that could impact your investment decision. See our latest analysis for Travere Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Travere Therapeutics' overall financial health at a glance.  Looking For More Investment Ideas Beyond Travere Therapeutics? If the Travere Therapeutics story has sharpened your thinking, use that momentum to widen your watchlist. A targeted screener can help you quickly surface other companies that fit the kind of balance sheet strength, income profile or upside potential you want to focus on next.  If capital preservation is high on your list, start with companies that pair resilient finances with steadier risk profiles through the 31 resilient stocks with low risk scores. For investors hunting for mispriced quality, survey a curated set of potential value opportunities using the 27 high quality undervalued stocks. If regular income is a priority, filter for stronger yield candidates and payout resilience through the 8 dividend fortresses.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Travere Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2673498095","isCrawlerRequest":true}